Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) CEO David M. Stack sold 28,885 shares of the company’s stock in a transaction dated Wednesday, January 10th. The shares were sold at an average price of $40.19, for a total transaction of $1,160,888.15. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Pacira Pharmaceuticals, Inc. (NASDAQ PCRX) traded down $0.72 on Friday, reaching $41.50. 1,030,000 shares of the company were exchanged, compared to its average volume of 712,847. The firm has a market cap of $1,713.07, a P/E ratio of -31.68 and a beta of 2.20. Pacira Pharmaceuticals, Inc. has a 12-month low of $29.81 and a 12-month high of $58.95. The company has a debt-to-equity ratio of 1.03, a quick ratio of 6.24 and a current ratio of 6.99.
Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its earnings results on Wednesday, November 8th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.04) by $0.15. The firm had revenue of $67.30 million during the quarter, compared to the consensus estimate of $68.99 million. Pacira Pharmaceuticals had a negative net margin of 18.25% and a negative return on equity of 13.77%. The company’s revenue was down 1.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.20 EPS. analysts expect that Pacira Pharmaceuticals, Inc. will post -0.85 EPS for the current year.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Public Employees Retirement System of Ohio increased its position in Pacira Pharmaceuticals by 7.5% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 40,174 shares of the company’s stock worth $1,509,000 after purchasing an additional 2,808 shares in the last quarter. Granahan Investment Management Inc. MA increased its position in Pacira Pharmaceuticals by 19.6% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 168,464 shares of the company’s stock worth $6,326,000 after purchasing an additional 27,609 shares in the last quarter. Highbridge Capital Management LLC increased its position in Pacira Pharmaceuticals by 4.4% during the 3rd quarter. Highbridge Capital Management LLC now owns 202,700 shares of the company’s stock worth $7,611,000 after purchasing an additional 8,618 shares in the last quarter. Cornerstone Capital Management Holdings LLC. acquired a new stake in Pacira Pharmaceuticals during the 3rd quarter worth approximately $2,267,000. Finally, Oppenheimer Asset Management Inc. increased its position in Pacira Pharmaceuticals by 207.4% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 7,375 shares of the company’s stock worth $277,000 after purchasing an additional 4,976 shares in the last quarter.
PCRX has been the subject of a number of research analyst reports. Zacks Investment Research downgraded shares of Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, October 9th. Canaccord Genuity reaffirmed a “buy” rating and set a $44.00 price objective (down previously from $48.00) on shares of Pacira Pharmaceuticals in a research note on Sunday, October 1st. Wedbush reaffirmed an “outperform” rating and set a $87.00 price objective on shares of Pacira Pharmaceuticals in a research note on Wednesday, October 25th. Needham & Company LLC reaffirmed a “buy” rating on shares of Pacira Pharmaceuticals in a research note on Tuesday, September 26th. Finally, BidaskClub downgraded shares of Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, January 6th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the stock. Pacira Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $49.00.
WARNING: This article was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/01/13/pacira-pharmaceuticals-inc-pcrx-ceo-david-m-stack-sells-28885-shares.html.
Pacira Pharmaceuticals Company Profile
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.